Search

96 Background: To investigate the impact of 5-alpha-reductase inhibitors (5-ARIs) usage on radiotherapy outcomes for localized prostate cancer. Methods: From our institutional database of over 2500 patients, we identified 203 patients on a 5-ARI. They were all treated with either external beam radiotherapy (EBRT) or brachytherapy for localized prostate cancer. Patients receiving a 5-ARI were analyzed according to the following prostate cancer progression criteria: a) progression of Gleason score or increase in cancer volume on the biopsy, b) first biopsy positive for cancer after being treated for urinary symptoms with a 5-ARI, and c) prostate-specific antigen (PSA) progression with or without a previous cancer diagnosis. Biochemical failure (BF) was defined by the Phoenix definition. Log-rank test was used for survival analysis. Results: At a median follow-up of 36 months (interquartile range [IQR] 22-52 months), 10 (4.9%) patients experienced BF. 52% of men demonstrated none of the progression criteria, 37% showed only one prostate cancer progression criteria and 11% showed two. Using a univariate analysis, PSA progression (p = 0.004) and appearance of a positive biopsy (p < 0.001) but not Gleason progression (p = 0.3) were a significant predictive factor of BF. With separate multivariate analysis adjusted for the CAPRA score (HR 1.7, 95% CI 1.2-2.3, p = 0.003), a rising PSA (HR 5.7, 95% CI 1.1-28.8, p = 0.04) and the number of cancer progression factors (HR 2.9, 95%CI 1.2-7.0, p = 0.02) remained adverse risk factors. Both Gleason score progression (p = 0.4) and first biopsy positive for cancer (p = 0.13) failed to remain significant. Age and obesity were not significant factors in univariate or multivariate analysis. Conclusions: A PSA progression experienced while under 5-ARI treatment before EBRT or brachytherapy is predictive of worse biochemical outcome. Such details should be considered when counseling men prior to radiation therapy.

16080 Background: Absolute changes in prostate specific antigen (PSA) values within the first year after radiotherapy can predict biochemical outcome on later follow up years. Other robust indicato...

15104 Background: Resectable pancreatic adenocarcinoma (PA) remains highly lethal. It is debatable whether adjuvant therapy can improve prognosis. Furthermore, what treatment should be delivered and for whom it is indicated is still of controversy. Methods: Between 1992–2004, retrospective data from the 141 patients who had a PA resected with curative intent in our centres were reviewed. Adjuvant treatment was as follows: 41 had chemoradiation (CRT), 1 neoadjuvant CRT, 10 chemotherapy alone (CT), 1 radiotherapy alone, and for 7 adjuvant treatment is unknown. The other 81 patients were observed. Overall survival (OS), relapse-free survival (RFS), locoregional and distant failure-free survival (LRFFS and DFFS) were analysed according to published prognostic factors. Kaplan-Meier curves with log-rank tests and Chi-2 coefficients were computed for the analysis. Results: Median age at diagnosis was 61 years. Overall, 63% of the patients were node positive, 67% had lymphovascular invasion (LVI), 71% had elevated CA-19.9 values and 50% operative blood loss >550cc. Table 1 displays these prognostics factors by treatment groups. For the entire cohort, median OS was 16.9 months; 1-year and 3-year OS were 76% and 43% respectively. No influence of treatment arm was found on OS (p=0.71). Negative nodes, normal CA-19.9 values, absence of LVI and blood loss [Table: see text] No significant financial relationships to disclose.